Robert Parker, MD
Obstetrics & Gynecology · Winston-Salem, NCNPI 1194715839
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. Bayer accounts for 67.6% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $1,651, 5.7 times the $288 reported in 2019.
Across 51 payments — averaging $44.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$2K
- AbbVie$143
- Pfizer$110
- Daiichi Sankyo Inc.$78
- Therapeuticsmd, Inc.$62
- Astellas Pharma US Inc$43
- plus $303 from 15 others
Across 303 payments — averaging $6934.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$799K
- Cepheid$522K
- Ventana Medical Systems, Inc.$253K
- Roche Molecular Systems, Inc.$124K
- Exeltis, USA Inc.$99K
- Mylan Inc.$94K
- plus $210K from 10 others
What the payments were for
- Travel & lodging$99043%
- Food & beverage$1,26656%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 10 | $1,540 |
| AbbVie | 9 | $143 |
| Pfizer | 8 | $110 |
| Daiichi Sankyo Inc. | 2 | $78 |
| Therapeuticsmd, Inc. | 4 | $62 |
| Astellas Pharma US Inc | 2 | $43 |
| Mayne Pharma Commercial LLC | 1 | $32 |
| Mission Pharmacal Company | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| AMAG Pharmaceuticals, Inc. | 2 | $24 |
| Biogen | 1 | $22 |
| Exeltis, USA Inc. | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| Myovant Sciences Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $17 |
| Roche Diagnostics Corporation | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Vertex | 1 | $15 |
| Merck | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
How this compares
$2,280 in reported general payments places this provider in the 80th percentile of 1,344 obstetrics & gynecology providers in North Carolina.
See all obstetrics & gynecology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other obstetrics & gynecology in Winston-Salem
- Jerry MatkinsCharlotte$481K
- Laura McKainWilmington$475K
- Leslie Hansen-LindnerCharlotte$372K
- Robin MatthewsClyde$217K
- Haywood BrownDurham$165K
- Jack IngeRaleigh$157K
- Geeta SwamyDurham$142K
- Karie LafleurAsheville$135K
- Ty RobinsonHigh Point$114K
- Shan BiscetteCharlotte$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.